Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. and UF startup Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs.
NovaBone’s New Bioactive Glass Syringe for Foot & Ankle
UF startup NovaBone Products, leader in synthetic biologics, announced the Alachua, Florida, company has made commercially available a new syringe for targeted delivery of its 45S5 bioactive glass putty device for the foot and ankle market. The newly launched syringe comes in both a 2.5cc and a 5cc formulation.
Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis
Atsena Therapeutics announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Tech Tuesday: Sinmat
From smartphones to medical equipment, microchips improve technologies and transform – even save – our lives. The technology -- and the company, Sinmat -- featured in today’s Tech Tuesday makes advanced microchips possible.
National Cade Prize for Innovation Names 21 Finalists
Judges for 2023’s National Cade Prize for Innovation named this year’s 21 Fibonacci Finalists. Finalists will compete to win $10,000 in their respective category group—Agriculture and Environmental, Healthcare/Biomedical, IT/Tech, Energy, and Wildcard. One of the five category winners will be selected as the Inventivity™ Grand Prize winner and take home an additional $50,000 prize. Two UF startups -- Lactovid and Analyz -- are listed among the Fibonacci Finalists.
Atsena Therapeutics Receives FDA Clearance of an Investigational Gene Therapy for X-Linked Retinoschisis
The U.S. Food and Drug Administration (FDA) has cleared Atsena Therapeutics' Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
Oragenics, Inc. Announces Private Placement
Oragenics, a UF startup, is partnering with healthcare investors. They've privately placed 404,728 shares of common stock and 404,728 shares of Series E Mirroring Preferred Stock to fight infectious diseases, including coronaviruses.
UF Startup and Innovate Accelerate Resident, Micro Nano Technologies, Receives DOE Recognition in $135M Emission Reduction Campaign
DOE Awards $135M to 40 Projects Driving US Industrial Sector Decarbonization, Including UF Startup 'Micro Nano Technologies,' in Pursuit of Nationwide Net-Zero Emissions Economy by 2050.
Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma.
Finding Fires With Lightning Speed
To address this urgent problem, Fire Neural Network (FNN), a company based in Gainesville, Florida, is utilizing artificial intelligence (AI) to expedite the identification of devastating wildfires from 24 hours to just 40 seconds.
